United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2007_register
executive
2010-09-22
article
Findings of Scientific Misconduct
Notices
D09002ee1bdda931d
D09002ee1bdda93bb
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
Office of the Secretary
originator
org
United States Government Agency or Subagency
Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case: Diana Layman, University of Oklahoma Health Sciences Center: Based on the report of an investigation conducted by the University of Oklahoma Health Sciences Center (OUHSC) and additional analysis conducted by the Office of Research Integrity during its oversight review, the U.S. Public Health Service (PHS) found that Ms. Diana Layman, Tribal Efforts Against Lead (TEAL) phlebotomist, OUHSC, engaged in scientific misconduct in research supported by National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), grant R01 ES008755. Specifically, Ms. Layman falsified research in the TEAL study by substituting or conspiring with another phlebotomist to substitute her blood or blood of another phlebotomist for blood samples of 10-15 child participants in the TEAL study. Ms. Layman has entered into a Voluntary Exclusion Agreement (Agreement) in which she has voluntarily agreed, for a period of three (3) years, beginning on May 30, 2007: (1) To exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government as defined in HHS' implementation of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension at 2 CFR part 376, et seq.; and (2) To exclude herself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.
72 FR 34690
https://www.govinfo.gov/app/details/FR-2007-06-25/E7-12170
E7-12170
fr25jn07-66
4150-31-P
https://www.govinfo.gov/app/details/FR-2007-06-25/E7-12170
https://www.govinfo.gov/content/pkg/FR-2007-06-25/html/E7-12170.htm
https://www.govinfo.gov/content/pkg/FR-2007-06-25/pdf/E7-12170.pdf
1 p.
34690
34690
72 FR 34690
Findings of Scientific Misconduct; Federal Register Vol. 72, Issue
NOTICE
E7-12170
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
4150-31-P
E7-12170
Notice.
Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case: Diana Layman, University of Oklahoma Health Sciences Center: Based on the report of an investigation conducted by the University of Oklahoma Health Sciences Center (OUHSC) and additional analysis conducted by the Office of Research Integrity during its oversight review, the U.S. Public Health Service (PHS) found that Ms. Diana Layman, Tribal Efforts Against Lead (TEAL) phlebotomist, OUHSC, engaged in scientific misconduct in research supported by National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), grant R01 ES008755. Specifically, Ms. Layman falsified research in the TEAL study by substituting or conspiring with another phlebotomist to substitute her blood or blood of another phlebotomist for blood samples of 10-15 child participants in the TEAL study. Ms. Layman has entered into a Voluntary Exclusion Agreement (Agreement) in which she has voluntarily agreed, for a period of three (3) years, beginning on May 30, 2007: (1) To exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government as defined in HHS' implementation of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension at 2 CFR part 376, et seq.; and (2) To exclude herself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.
Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8800.
Scientific misconduct findings; administrative actions:
Layman, Diana,
Federal Register
Vol. 72, no. 121
Office of the Federal Register, National Archives and Records Administration
2007-06-25
continuing
daily
deposited
born digital
398 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2007-06-25
P0b002ee18095f4fa
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr25jn07
https://www.govinfo.gov/app/details/FR-2007-06-25
https://www.govinfo.gov/content/pkg/FR-2007-06-25/pdf/FR-2007-06-25.pdf
https://www.govinfo.gov/content/pkg/FR-2007-06-25/xml/FR-2007-06-25.xml
fdlp
34595
34981
DGPO
2010-09-22
2023-05-02
FR-2007-06-25
machine generated
eng
FR
FR-2007-06-25
72
121